Comparing incomparables with the wrong analytics

Anticoagulation, disability, intracranial hemorrhage, and mortality in acute cerebral vein thrombosis

Abdulaziz Saleh Almulhim, Saad Fallatah, Ivo L Abraham

Research output: Contribution to journalLetter

1 Citation (Scopus)

Abstract

Significant progress has been made in the prevention and management of hypercoagulation. Unfractionated heparin (UF) and low molecular weight heparin (LMWH) are indicated for acute cerebral vein thrombosis with or without intracranial hemorrhage (ICH). A recent meta-analysis of four trials comparing UF and LMWH aimed to evaluate the efficacy and safety of both agents in terms of disability, intracranial hemorrhage, and mortality. However, several methodological aspects of the meta-analysis warrant further discussion. It appears that the disability outcome was not sufficiently harmonized by design or statistical standardization, some inputs could not be validated, incorrect statistical analyses were performed, major results could not be replicated, and conclusions were not supported by the statistical results. The conclusion of a statistically significant reduction in mortality is not supported by the data.

Original languageEnglish (US)
Pages (from-to)110-111
Number of pages2
JournalThrombosis Research
Volume178
DOIs
StatePublished - Jun 1 2019

Fingerprint

Cerebral Veins
Intracranial Thrombosis
Intracranial Hemorrhages
Low Molecular Weight Heparin
Heparin
Meta-Analysis
Mortality
Safety

Keywords

  • Anticoagulation
  • Cerebral vein thrombosis
  • Disability
  • Low molecular weight heparin
  • Meta-analysis
  • Mortality

ASJC Scopus subject areas

  • Hematology

Cite this

Comparing incomparables with the wrong analytics : Anticoagulation, disability, intracranial hemorrhage, and mortality in acute cerebral vein thrombosis. / Almulhim, Abdulaziz Saleh; Fallatah, Saad; Abraham, Ivo L.

In: Thrombosis Research, Vol. 178, 01.06.2019, p. 110-111.

Research output: Contribution to journalLetter

@article{e2cc1c9d5c8947f8a84b6046eb2ba6f6,
title = "Comparing incomparables with the wrong analytics: Anticoagulation, disability, intracranial hemorrhage, and mortality in acute cerebral vein thrombosis",
abstract = "Significant progress has been made in the prevention and management of hypercoagulation. Unfractionated heparin (UF) and low molecular weight heparin (LMWH) are indicated for acute cerebral vein thrombosis with or without intracranial hemorrhage (ICH). A recent meta-analysis of four trials comparing UF and LMWH aimed to evaluate the efficacy and safety of both agents in terms of disability, intracranial hemorrhage, and mortality. However, several methodological aspects of the meta-analysis warrant further discussion. It appears that the disability outcome was not sufficiently harmonized by design or statistical standardization, some inputs could not be validated, incorrect statistical analyses were performed, major results could not be replicated, and conclusions were not supported by the statistical results. The conclusion of a statistically significant reduction in mortality is not supported by the data.",
keywords = "Anticoagulation, Cerebral vein thrombosis, Disability, Low molecular weight heparin, Meta-analysis, Mortality",
author = "Almulhim, {Abdulaziz Saleh} and Saad Fallatah and Abraham, {Ivo L}",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.thromres.2019.04.009",
language = "English (US)",
volume = "178",
pages = "110--111",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Comparing incomparables with the wrong analytics

T2 - Anticoagulation, disability, intracranial hemorrhage, and mortality in acute cerebral vein thrombosis

AU - Almulhim, Abdulaziz Saleh

AU - Fallatah, Saad

AU - Abraham, Ivo L

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Significant progress has been made in the prevention and management of hypercoagulation. Unfractionated heparin (UF) and low molecular weight heparin (LMWH) are indicated for acute cerebral vein thrombosis with or without intracranial hemorrhage (ICH). A recent meta-analysis of four trials comparing UF and LMWH aimed to evaluate the efficacy and safety of both agents in terms of disability, intracranial hemorrhage, and mortality. However, several methodological aspects of the meta-analysis warrant further discussion. It appears that the disability outcome was not sufficiently harmonized by design or statistical standardization, some inputs could not be validated, incorrect statistical analyses were performed, major results could not be replicated, and conclusions were not supported by the statistical results. The conclusion of a statistically significant reduction in mortality is not supported by the data.

AB - Significant progress has been made in the prevention and management of hypercoagulation. Unfractionated heparin (UF) and low molecular weight heparin (LMWH) are indicated for acute cerebral vein thrombosis with or without intracranial hemorrhage (ICH). A recent meta-analysis of four trials comparing UF and LMWH aimed to evaluate the efficacy and safety of both agents in terms of disability, intracranial hemorrhage, and mortality. However, several methodological aspects of the meta-analysis warrant further discussion. It appears that the disability outcome was not sufficiently harmonized by design or statistical standardization, some inputs could not be validated, incorrect statistical analyses were performed, major results could not be replicated, and conclusions were not supported by the statistical results. The conclusion of a statistically significant reduction in mortality is not supported by the data.

KW - Anticoagulation

KW - Cerebral vein thrombosis

KW - Disability

KW - Low molecular weight heparin

KW - Meta-analysis

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=85064321188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064321188&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2019.04.009

DO - 10.1016/j.thromres.2019.04.009

M3 - Letter

VL - 178

SP - 110

EP - 111

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -